NISPA

Nijmegen Institute for Scientist-Practitioners in Addiction

Severity of psychiatric and physical problems is associated with lower quality of life in methadone patients in Indonesia.

TitelSeverity of psychiatric and physical problems is associated with lower quality of life in methadone patients in Indonesia.
PublicatietypeJournal Article
Jaar van publicatie2013
AuteursIskandar S, van Crevel RR, Hidayat T, Siregar IMP, Achmad TH, van der Ven AJAM, DeJong CA
UitgaveAm J Addict
Volume22
Nummer5
Pagina's425-31
Publicatiedatum2013 Sep-Oct
ISSN1521-0391
Samenvatting

BACKGROUND AND OBJECTIVES: The goal of methadone maintenance treatment (MMT) is to reduce the harm and to improve patients' quality of life (Qol). However, the Qol is also influenced by other co-occurring disorders. Data regarding the Qol and the co-occurrence of these disorders is lacking in low-middle income countries. We therefore describe the prevalence of physical, psychiatric, and drug abuse co-occurring disorders among MMT patients in Indonesia and determine the association between the severity of the co-occurring disorders and the Qol.

METHODS: Data were collected in 112 injection drug abusers (IDUs) attending a MMT program in West Java, Indonesia, using validated questionnaires, medical records and laboratory testing. For comparison, 154 IDUs not enrolled in MMT were recruited by respondent driven sampling.

RESULTS: The most frequent co-occurring disorders were hepatitis C (92%), HIV (77%), benzodiazepine abuse (56%), and anxiety disorders (32%). IDUs in MMT had one (26%), two (47%), or three (27%) co-occurring disorders. Higher severity in psychiatric and physical problems was associated with poorer Qol. IDUs not enrolled in MMT had similar co-occurring problems.

CONCLUSIONS: The prevalence of co-occurring disorders in IDUs in Indonesia is high and they influence their Qol.

SCIENTIFIC SIGNIFICANCE: Therefore, comprehensive treatment, especially focusing on the common co-occurring disorders should be provided in MMT to improve the Qol.

DOI10.1111/j.1521-0391.2013.00334.x
Alternatieve uitgaveAm J Addict
PubMed ID23952886